Options are subject to the following vesting conditions:
(a) when the Company determines to progress NNZ-2591 to a Phase 2b or Phase 3 clinical trial following a positive Phase
2 clinical trial outcome, or executes a partnering transaction for NNZ-2591;
(b) when the Company executes a partnering transaction for trofinetide outside North America, or submits a Marketing
Authorisation Application for trofinetide in the European Union, the United Kingdom or Japan.
(c) on acceptance by the US FDA of the filing of a New Drug Application for trofinetide.
If we can pass those hurdles, $8+ for sure.
Options are subject to the following vesting conditions:(a) when...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |